SEDLIS/PETERSPost-Hysterectomy Adjuvant Assessment

Pathologic Risk Factors

Clinical pearl

Peters Criteria (GOG 109) defines the cohort benefiting from chemoradiation, while Sedlis Criteria (GOG 92) defines the cohort benefiting from radiation alone to reduce local recurrence.

Adjuvant Status

Surveillance

Clinical Strategy

Criteria not met for adjuvant therapy. Routine surveillance is typically indicated.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Patients with FIGO Stage IA2, IB, or IIA cervical cancer post-radical hysterectomy and pelvic lymphadenectomy.

Used to decide between observation, pelvic radiation alone (Sedlis), or concurrent chemoradiation (Peters).

Clinical Pearls

Actionable Management

Finding	Adjuvant Therapy
Sedlis Positive (2+ factors)	External Beam Radiation Therapy (EBRT) alone.
Peters Positive (1+ factor)	Concurrent Chemoradiation (EBRT + Cisplatin).

Clinical Note

The Peters criteria identifying "High Risk" features proved that the addition of cisplatin to radiation significantly improved overall survival compared to radiation alone in this setting.

Last Comprehensive Review: 2026

SEDLIS/PETERSPost-Hysterectomy Adjuvant Assessment

Pathologic Risk Factors

Clinical pearl

Peters Criteria (GOG 109) defines the cohort benefiting from chemoradiation, while Sedlis Criteria (GOG 92) defines the cohort benefiting from radiation alone to reduce local recurrence.

Adjuvant Status

Surveillance

Clinical Strategy

Criteria not met for adjuvant therapy. Routine surveillance is typically indicated.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Patients with FIGO Stage IA2, IB, or IIA cervical cancer post-radical hysterectomy and pelvic lymphadenectomy.

Used to decide between observation, pelvic radiation alone (Sedlis), or concurrent chemoradiation (Peters).

Clinical Pearls

Actionable Management

Finding	Adjuvant Therapy
Sedlis Positive (2+ factors)	External Beam Radiation Therapy (EBRT) alone.
Peters Positive (1+ factor)	Concurrent Chemoradiation (EBRT + Cisplatin).

Clinical Note

The Peters criteria identifying "High Risk" features proved that the addition of cisplatin to radiation significantly improved overall survival compared to radiation alone in this setting.

Last Comprehensive Review: 2026

Sedlis/Peters Criteria

Pathologic Risk Factors

Surveillance

When to Use

When to Use

How it Works

Sedlis Criteria (Intermediate Risk)

Peters Criteria (High Risk)

Clinical Pearls

Actionable Management

Clinical Note

The Evidence

Key References

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

Related Tools

Recent Journal Updates

Sedlis/Peters Criteria

Pathologic Risk Factors

Surveillance

When to Use

When to Use

How it Works

Sedlis Criteria (Intermediate Risk)

Peters Criteria (High Risk)

Clinical Pearls

Actionable Management

Clinical Note

The Evidence

Key References

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

Related Tools

Recent Journal Updates